Craig Anderson, PhD, is a professor of neurology and epidemiology and the director of the Brain Health Program at the George Institute.

Triple-Combination Blood Pressure Pill Reduces Ischemic Stroke Risk, With Craig Anderson, PhD

GMRx2, a combination of 3 low-dose blood pressure medications in a single pill, has proven its efficacy in substantially reducing 

 risk in patients with intracerebral hemorrhage (ICH), according to data from the TRIDENT phase 3 trial.

Intracerebral hemorrhage is the direct contributor to a disproportionate percentage of stroke-related morbidity and mortality. Among its primary causes is chronic 

, another famously under-managed condition affecting a substantial proportion of the population. Blood pressure reduction is therefore a cornerstone of modern ICH treatment and prevention of further stroke.

“One of the problems we’ve had in blood pressure control for secondary prevention after stroke is just achieving the targets, whether that’s <140 or, more stringently, <130,” Craig Anderson, PhD, professor of neurology and epidemiology, director of the Brain Health Program at the George Institute, and principal investigator, told 

 in an exclusive interview. “It’s very challenging to do that in clinical practice – most patients will require multiple drugs and that causes problems with medication adherence. Our trial shows that achieving blood pressure <130 is achievable, and that the triple pill approach can do it very effectively compared to standard treatment.”

The Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) was a multicenter, international, double-blinded, placebo-controlled, parallel-group, randomized controlled trial comparing more intensive blood pressure control through the “triple pill” GMRx2 on top of standard care to treatment with matched placebo. Anderson and colleagues aimed to assess the triple pill’s efficacy and safety in preventing recurrent ischemic strokes in patients with a history of ICH and high, normal, or low-grade hypertension. The trial was conducted across 58 locations worldwide.

Patients were eligible for inclusion if they had a history of primary ICH confirmed via imaging and an average of 2 resting systolic blood pressure (SBP) levels measured 5 minutes apart in the range 130-160 mmHg, among other criteria. Patients taking an ACE inhibitor which could not be switched to a study alternative or who had severe hepatic impairment, significant hyperkalemia, or hyponatremia, among other criteria, were excluded.

Enrolled patients were randomly assigned to receive either GMRx2 – a combination of telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg – or placebo, both of which were daily pills taken orally for an average of 72 months. The study’s primary outcome was time to first occurrence of recurrent stroke, whether ischemic or hemorrhagic. Secondary outcomes included time to first occurrence of recurrent ICH, mortality, major adverse cardiovascular events, and change in SBP, among others.

A total of 1670 patients were ultimately enrolled, all of whom had SBP within 130-160 mmHg. Over the course of the study, stroke occurred in 4.6% of patients receiving GMRx2 versus 7.4% receiving placebo. Major adverse cardiovascular events occurred in 6.6% of GMRx2 recipients compared to 9.8% of placebo recipients, resulting in a 33% reduction. Additionally, Anderson and colleagues noted a 9 mmHg greater SBP reduction in the GMRx2 arm.

“The important thing about TRIDENT was the additional benefit that was achieved by most of the patients already on a treatment,” Anderson told 

. “Most people were on multiple drugs, and most people were within clinicians’ understanding of good control. And even with that, the addition of GMRx2 allowed them to achieve this amazingly extra benefit.”

Editors’ Note: Anderson reports disclosures with the National Health and Medical Research Council of Australia, the Medical Research Council of the UK, Takeda, Credit, Genesis, and Penumbra, Inc.

Anderson C, Chow C, de Silva H, et al. Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage. 

. 2026;394(16):1571-1582. doi:10.1056/NEJMoa2515043

Schrag M, Kirshner H. Management of Intracerebral Hemorrhage: JACC Focus Seminar. 

The George Institute. Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT). ClinicalTrials.gov Identifier: NCT02699645. Updated September 12, 2025. Accessed April 22, 2026. 

https://clinicaltrials.gov/study/NCT02699645

Videos

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Growth hormone deficiency in adults remains a commonly underappreciated and underrecognized diagnosis in endocrinology. Despite quietly eroding body composition, metabolic health, and quality of life, it has long been managed with a daily injection regimen that many patients do not sustain.

With lonapegsomatropin (Skytrofa), developed as TransCon hGH, earning US Food and Drug Administration approval for adult GH deficiency in July 2025, clinicians now have a once-weekly alternative. New long-term extension data presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 by Julie Silvertein, MD, a Professor of Medicine and Neurological Surgery and Medical Director of the Pituitary Center at Washington University, offer a more comprehensive picture of how it performs over time.

 Once-weekly prodrug of somatropin (human growth hormone)

 Uses a pH- and temperature-sensitive linker to transiently inactivate somatropin; active, unmodified hGH is released gradually over 7 days

 August 2021, for pediatric GH deficiency; July 28, 2025, for replacement of endogenous GH in adults with GH deficiency

 Phase 3 foresiGHt trial, in which lonapegsomatropin demonstrated superiority over placebo on trunk fat reduction and lean mass gain at 38 weeks

 Ascendis Pharma (marketed as Skytrofa in the US)

Lonapegsomatropin’s approval for this indication built upon previous August 2021 approval for the treatment of pediatric growth hormone deficiency in children ≥ 1 year of age weighing ≥ 26 pounds. The latest approval was based on results from foresiGHt, a phase 3 randomized, parallel-arm, placebo-controlled, double-blind, and active-controlled clinical trial that compared the efficacy and safety of weekly lonapegsomatropin with weekly placebo and daily somatropin in adults with growth hormone deficiency.

The trial randomly assigned 259 adults with growth hormone deficiency aged 23 to 80 years old in a 1:1:1 ratio, titrated to receive a target fixed dose of lonapegsomatropin, placebo, or daily hGH. Randomization was based on age and oral estrogen intake, with approximately equivalent hGH mg/week for lonapegsomatropin and daily hGH.

Of the 248 participants who completed treatment in the foresiGHt trial, 220 (88.7%) continued into the extension trial for up to 90 weeks and 202 (91.8%) participants completed 52 weeks of treatment in the extension trial.

Across 236 lonapegsomatropin-treated participants from both trials, the most common AEs were nasopharyngitis (9.7%), upper respiratory tract infection (9.3%), headache (8.1%), COVID-19 (7.2%), arthralgia (6.4%), and injection site reactions (5.1%). Most were mild or moderate, and treatment discontinuations due to AEs occurred in 3.8% of participants.

Results showed mean hemoglobin A1c remained stable within the reference range throughout all 90 weeks. Additionally, immunogenicity was low, with anti-hGH and anti-lonapegsomatropin antibodies each detected in 3.4% of participants and anti-PEG binding antibodies in 0.9%. All were low titer, transiently detected, and no neutralizing antibodies were identified.

Of note, weekly average IGF-1 SDS was maintained within the normal reference range through week 90 across all groups. Participants previously on placebo showed appropriate IGF-1 increases after initiating lonapegsomatropin, converging toward the reference range during re-titration and remaining stable thereafter.

Additionally, body composition improved across all 3 prior-treatment groups from the foresiGHt baseline through week 90, with reductions in trunk percent fat, trunk fat mass, and visceral adipose tissue, alongside gains in total body lean mass and trunk lean mass.

Patient-reported outcomes also reflected durable benefit. Using TRIM-AGHD, responder rates at week 90, defined as a reduction of ≥ 10 points from baseline, were 43.5%, 40.6%, and 35.8% in the lonapegsomatropin/lonapegsomatropin, placebo/lonapegsomatropin, and somatropin/lonapegsomatropin groups, respectively, with mean score reductions of approximately 19-23 points across groups.

Silverstein JM, Gilis-Januszewska A, Doknic M, et al. Long-term Safety and Efficacy of Lonapegsomatropin in Adults With Growth Hormone Deficiency: Results From a 52-Week Open-Label Extension Trial. Presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas, Nevada, April 22-24, 2026.

Brooks A. FDA Approves Lonapegsomatropin-tcgd (Skytrofa), Formerly TransCon hGH, for Adult Growth Hormone Deficiency. HCPLive. July 28, 2025. Accessed April 22, 2026. 

https://www.hcplive.com/view/fda-approves-lonapegsomatropin-tcgd-skytrofa-formerly-transcon-hgh-for-adult-growth-hormone-deficiency

Articles

Adult growth hormone deficiency is frequently overlooked and historically burdensome to treat because of daily injections. Once-weekly lonapegsomatropin, FDA-approved in July 2025, now has longer-term extension data through 90 weeks following the phase 3 foresiGHt program. Safety was consistent with mostly mild-to-moderate infections, headache, arthralgia, and limited injection-site reactions, with few discontinuations. Glycemic control and IGF-1 SDS remained stable within reference ranges, immunogenicity was low, and durable improvements were observed in body composition and patient-reported treatment impact.

Results from the 52-week open-label extension trial highlight strong safety and efficacy outcomes with lonapegsomatropin in adults with growth hormone deficiency.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Lonapegsomatropin Proves Long-Term Benefit for Adult GHD in Phase 3 foresiGHt Extension Trial

The United States Food and Drug Administration (US FDA) has approved dupilumab (Dupixent) for children aged 2 to 11 years with 

 (CSU) that remains symptomatic despite H1 antihistamine treatment, according to a joint announcement from Regeneron and Sanofi.

 The decision extends the drug’s prior US CSU indication in adults and adolescents aged 12 years and older.

“With this approval, Dupixent has become the first biologic medicine in the U.S. for young children suffering from uncontrolled chronic spontaneous urticaria, an unpredictable skin disease that impacts quality of life during these children’s most formative years,” George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent, said in a statement.

 “Dupixent is now approved for 9 different allergy-related conditions, from asthma to atopic dermatitis, and this is the fifth of these indications now extended to young children. The FDA’s authorization reinforces our medicine’s well-established safety profile and potential to transform outcomes for chronic diseases driven in part by type 2 inflammation impacting some of the most vulnerable populations. As the most widely used innovative branded antibody medicine, Dupixent has the potential to change yet another treatment paradigm.”

According to the announcement, the pediatric label expansion was based primarily on the phase 3 LIBERTY-CUPID program, using efficacy and safety extrapolation from randomized trials in older patients and pharmacokinetic data from the single-arm CUPIDKids study in children aged 2 to 11 years.

 In Study A and Study C, both replicate double-blind, placebo-controlled trials in patients aged 6 years and older who were symptomatic despite antihistamines and naïve to anti-IgE therapy, dupilumab significantly improved weekly itch severity score (ISS7) and weekly urticaria activity score (UAS7) vs placebo at week 24, the companies said.In adults and adolescents, dupilumab also increased the likelihood of well-controlled disease (UAS7 ≤6) and complete response (UAS7 = 0) at 24 weeks.

Study B enrolled patients aged 12 years and older who were symptomatic despite antihistamines and were inadequate responders or intolerant to anti-IgE therapy, providing additional safety data, according to the release. CUPIDKids was a single-arm phase 3 trial designed to assess safety, efficacy, and pharmacokinetics over 24 weeks; its primary endpoint was serum dupilumab concentration over time, including trough levels at weeks 12 and 24. No numerical efficacy results from CUPIDKids were disclosed in the release.

CSU is characterized by recurrent wheals, pruritus, or both for at least 6 weeks without a specific external trigger and can substantially impair sleep, school functioning, and quality of life. International guidance generally recommends second-generation H1 antihistamines as first-line therapy, with dose escalation and then biologic treatment for refractory disease. Omalizumab has been a standard biologic option for antihistamine-refractory CSU in older patients, although pediatric options for children younger than 12 years have been more constrained.

Dupilumab is a fully human monoclonal antibody that blocks interleukin 4 and interleukin 13 signaling. It is already approved across multiple type 2 inflammatory diseases, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.

 Its role in CSU has been of interest because not all patients respond adequately to antihistamines or anti-IgE therapy, and CSU pathobiology may include overlapping inflammatory pathways beyond mast cell and IgE-mediated signaling.

Setting: uncontrolled on H1 antihistamines  

Prior CSU use: adults, age 12 years and up  

Safety findings in the CSU development program were described by the sponsors as generally consistent with the established dermatologic safety profile of dupilumab.

 In Studies A, B, and C, the most common adverse event (AE) occurring more often with dupilumab than placebo was injection-site reaction.

The companies also said no new AEs were identified in children aged 2 to 11 years with CSU, with pediatric safety additionally supported by experience in other approved indications.

 Still, clinicians will likely want more detailed pediatric CSU-specific safety and effectiveness data once full prescribing information and peer-reviewed reports become available.

The regulatory pathway also warrants caution in interpretation. This pediatric expansion appears to rely substantially on extrapolation from older populations plus pharmacokinetic bridging rather than a fully powered pediatric efficacy trial.

 That approach is common in pediatric drug development, but it leaves unanswered questions about magnitude of benefit in younger children, comparative effectiveness vs other advanced therapies, and durability beyond 24 weeks.

For practice, the approval adds a biologic option for children with antihistamine-refractory CSU, but its place in therapy will depend on payer coverage, family acceptance of subcutaneous treatment, and how clinicians weigh it against established guideline sequencing. More detailed FDA documentation and full trial publication should clarify the evidence base for this younger age group.

Regeneron Pharmaceuticals, Inc; Sanofi. Dupixent (dupilumab) approved in the U.S. as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria (CSU). GlobeNewswire. April 22, 2026. Accessed April 22, 2026. 

https://www.globenewswire.com/news-release/2026/04/22/3279470/0/en/dupixent-dupilumab-approved-in-the-u-s-as-the-first-biologic-medicine-for-young-children-with-uncontrolled-chronic-spontaneous-urticaria-csu.html

Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma: LIBERTY ASTHMA TRAVERSE. Eur Respir J. 2022;60(3):2102791.

The FDA has expanded dupilumab’s chronic spontaneous urticaria indication to children aged 2–11 years who remain symptomatic despite H1 antihistamines, extending prior approval in adolescents and adults. The decision addresses a major therapeutic gap for antihistamine-refractory pediatric CSU, where biologic options have been limited. Support came primarily from the phase 3 LIBERTY-CUPID program, leveraging efficacy/safety extrapolation from patients aged ≥6 years and pharmacokinetic bridging from the single-arm CUPIDKids study. Safety appeared consistent with dupilumab’s established profile.

FDA approved dupilumab for children aged 2 to 11 years with chronic spontaneous urticaria uncontrolled by H1 antihistamines.

FDA Expands Dupilumab to Children Aged 2 to 11 Years With Uncontrolled CSU

Anick Bérard PhD, a researcher at CHU Sainte-Justine in Montreal, professor at the University of Montreal, and an adjunct professor Université Claude Bernard Lyon 1.

ICS Not Linked to Birth Defect Risk in Early Pregnancy, With Anick Bérard, PhD

First-trimester exposure to inhaled corticosteroid (ICS) monotherapy, montelukast, and combination therapies with long-acting beta agonists (LABA) did not show an increased risk of major congenital malformations compared with no

 medication use, according to new population-based data.

, Anick Bérard, PhD, from CHU Sainte-Justine, described these results as “reassuring.” She mentioned how many women with unexpected pregnancies may not find out that they are pregnant until 6 or 7 weeks later. However, this data shows that taking asthma medication during pregnancy is safe.

“The GINA guidelines say asthmatic women should be treated in pregnancy, and our study [with] a large cohort [is]… confirming what the guidelines are saying,” Bérard said. She noted that smaller datasets originally informed these guidelines, standing for Global Initiative for Asthma, whereas the current study provides confirmation using a substantially larger cohort.

Bérard and colleagues’ analysis included a large cohort of > 44,000 singleton births among women with asthma and compared multiple commonly used controller therapies during the first trimester. Regimens included montelukast, inhaled corticosteroids (ICS), ICS plus long-acting beta agonists (LABA), and montelukast plus ICS plus LABA combination.

She also cautioned that the study does not address all pregnancy outcomes, such as preterm birth or low birth weight, which require further investigation. Additionally, she noted that the cohort largely included women with private insurance, indicating a higher socioeconomic profile that may limit generalizability.

Overall, the data support ongoing use of ICS monotherapy and ICS/LABA combinations when clinically indicated.

“It's reassuring for prescribers, but also for pregnant women themselves, because we're all worried about major congenital malformation,” Bérard said. “The quality of life and health of the mother is as important as the health of the fetus, although in pregnancy, we prescribe for a maternal condition, but we don't always worry about the health of the mom. We worry about the health of the unborn child. Results like ours will put women at ease that they can, and they should be treated. It will have a beneficial impact on themselves, but it will not have an impact on their fetus, at least during the first trimester.”

Watch part 1 of our interview with Bérard here: 

Asthma Controllers Safe in First Trimester, With Anick Bérard, PhD

Jiao XF, Leal LF, Ducharme FM, Tse SM, Bérard A. First-trimester asthma controller medication use and major congenital malformation risk in offspring of women with asthma: A nationwide population-based cohort study. 

In an interview, Bérard discusses cohort data showing no increased risk of major congenital malformations with ICS or ICS/LABA use in first trimester.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Rachael Sood, NP, is a diabetes nurse practitioner and Owner and CEO of The Diabetes Collective.

The FDA has approved an expanded indication for teplizumab-mzwv (Tzield) to delay the onset of stage 3 

 in children as young as 1 year of age diagnosed with stage 2 disease, extending the therapy's reach from its prior lower age limit of 8 years. The approval, granted under priority review, makes teplizumab the first disease-modifying therapy indicated for this younger age group with stage 2 type 1 diabetes.

The expanded approval indicates teplizumab to delay progression to stage 3 type 1 diabetes in patients with stage 2 disease starting at age 1 year

The decision lowers the prior approved age threshold from 8 years to 1 year

Approval is supported by the PETITE-T1D phase 4, single-arm, open-label study in children under 8 years with stage 2 T1D

Teplizumab is the first disease-modifying therapy approved to delay progression from stage 2 to stage 3 type 1 diabetes

Type 1 diabetes is an autoimmune condition in which immune-mediated destruction of insulin-producing beta cells begins years before clinical symptoms emerge. In young children, this progression can be particularly rapid and difficult to detect, and the burden of stage 3 disease management is compounded by developmental factors including small body size and full dependence on caregivers. Stage 2 disease is defined by the presence of 2 or more type 1 diabetes-related autoantibodies alongside dysglycemia in the absence of symptoms.

The expanded indication is supported by 1-year data from PETITE-T1D, a phase 4 single-arm, open-label, multicenter study evaluating the safety and pharmacokinetics of teplizumab in 23 children < 8 years of age with stage 2 type 1 diabetes. The regimen consists of a once-daily intravenous infusion administered over 14 consecutive days. Parent company Sanofi noted that a supplemental review is also underway for a potential indication to delay progression of stage 3 disease in patients ≥ 8 years of age recently diagnosed with stage 3 type 1 diabetes.

Check out this interview with Rachael Sood, NP, where she discusses what this expanded approval means for clinical practice, how to identify and counsel families of young children with stage 2 type 1 diabetes, and the evolving role of disease-modifying therapy in this population.

: What is the clinical significance of expanding teplizumab use to children as young as 1 year with stage 2 type 1 diabetes?

: This is huge. This is huge news. When I woke up and saw this news, this is the hugest news, probably for this entire year. People that get diagnosed with type 1 diabetes have a complete change in lifestyle. They have to make so many extra decisions. They are dependent on insulin. They are traumatized. They are most often diagnosed in emergency rooms. Many times when we're talking about kids, people don't recognize symptoms early, because kids are kids. They don't really complain. They're just having fun. ‘Oh, I'm hungry, I'm dehydrated, oh, I'm always sick’ but, you know, they just don't complain. They don't recognize things, and we're definitely not getting to our children as quickly.

We also have an issue with access to care. In pediatric clinics, you're seeing 25-30 people a day, and it's really hard to keep up, so these people just go under the radar. Now that this indication is open, I'm hoping that it opens up the opportunity to maybe screen patients to see if they have type 1 diabetes, even early stages, because we actually do have a treatment for them now. I think maybe that was a barrier in some pediatric clinics, that we don't have anything to do about it except just insulin. So why screen or why recognize? I don't know. I don't know what the gate is to you know, but I'm hoping this opens it.

 How might this approval change the way clinicians approach early screening and identification of at-risk patients?

I'm hoping that this indication increases awareness that we do have a medication for this. And just going to the last point, I kind of jumped the gun, but now we have a medication, so let's screen and see, because if they are, then we know, and then we can get them this treatment if they desire it. Now we actually have another option to give them instead of just waiting or referral to clinical trials, or just waiting so your blood sugar gets high and you need insulin. You know, ‘come back when you need insulin.’ I hate that phrase, and I hope we start seeing and hearing less of it.

What factors should clinicians consider when selecting young patients for teplizumab therapy?

Factors to consider for teplizumab, so anyone that has type 1 diabetes stage 2 is going to be a candidate for teplizumab or Tzield, a CD3 directed monoclonal antibody. This is a medication that we make sure that someone is in good health. Obviously, when we give the medication, we do screen people to see if they have any really bad, active viral infections or things like that. It's very, very rare, so most people that are in type 1 stage 2 are candidates for this IV infusion.

How do you see this approval shaping the future of type 1 diabetes management and early intervention?

I think we're not ready, and I don't want to say that, but I'm going to be honest, because we are seeing an increase in type 1. We are seeing an increase in autoimmune diseases just across the US, here, where I am, and across the globe, we are seeing more autoimmune. I think more people are getting more aware of immunology, and we're starting to see that branch off just in the endocrine space, and really in the primary care space, people are getting more interested and invested in it.

I hope this FDA approval kind of kick starts that, hey, like, there's a medication for this. Like there was a reason that this came about. There was a reason to study this. There's a reason to screen, there's a reason to give people time. There's a reason to recognize and see that if we want to keep kids out the hospital, if we want to give mom a few extra years, even if this delays progression for a few years, maybe it doesn't hold the beta cells completely, but if it buys time, that time is so precious, and people deserve that time, kids, moms, parents, families. They deserve this time to not have the burden of having to take insulin and watching their blood sugar 24/7.

Editors’ note: Sood reports no relevant disclosures.

Campbell P. FDA Expands Teplizumab Approval to Children 1 Year & Older to Delay Type 1 Diabetes Onset. HCPLive. April 22, 2026. Accessed April 22, 2026. 

https://www.hcplive.com/view/fda-expands-teplizumab-approval-to-children-as-young-as-1-year-to-delay-type-1-diabetes-onset

US Centers for Disease Control and Prevention. Type 1 Diabetes. May 15, 2024. Accessed April 22, 2026. 

https://www.cdc.gov/diabetes/about/about-type-1-diabetes.html

FDA expanded teplizumab-mzwv’s indication to delay progression to stage 3 type 1 diabetes in children with stage 2 disease down to age 1 year, following priority review. Stage 2 is defined by multiple T1D autoantibodies with dysglycemia and no symptoms, a period when beta-cell destruction is already underway and can be rapid in very young children. Support comes from PETITE‑T1D (phase 4, single-arm; n=23; <8 years) evaluating safety and pharmacokinetics with a 14‑day IV infusion course. Expanded eligibility may catalyze earlier screening and counseling.

Sood discusses the FDA expansion of teplizumab to children as young as age 1 with stage 2 T1D and the implications for early intervention and delaying disease progression.

Type 1 Diabetes

Teplizumab Expansion Redefines Early Type 1 Diabetes Intervention, With Rachael Sood, NP

Rory Sayres, PhD, is a researcher in the Health AI group in Google Research who focuses on intelligence augmentation of medical experts using machine-learning-based assistance.

This interview highlights new data assessing whether artificial intelligence (AI)–powered tools can help consumers better understand dermatology cases.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

AI Tool Use Linked with Understanding of Skincare Issues, With Rory Sayres, PhD, and Yun Liu, PhD

Propensity-matched data link empagliflozin to lower risk of CV events, AKI, and other outcomes versus dapagliflozin in type 2 diabetes.

Type 2 Diabetes

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Real-World Analysis Links Empagliflozin to Lower Cardiorenal Event Risk Versus Dapagliflozin in T2D

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

A recent presentation at AACE 2026 highlights the drastically increased risk of mortality, sepsis, diabetic ketoacidosis, and recurrent acute pancreatitis after GLP-1 initiation.

GLP-1 Use in Patients with Prior Alcohol-Related Pancreatitis Dangerously Increases DKA, Mortality Risk

A recent study from AACE 2026 has indicated the value of bariatric surgery in adults with type 1 diabetes – and emphasized the need for closer perioperative management.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Bariatric Surgery in T1D Causes Sustained Weight Loss, Improves Comorbidities

Alva discusses infrastructure gaps, training demands, and unmet psychiatric need amid accelerated policy momentum for psychedelic therapies.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

PTSD

Psychiatry Infrastructure Lags Psychedelic Momentum, With Gus Alva, MD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

From Eosinophils to Image Biomarkers: The Evolving Science of Biologic Selection in Asthma and COPD

Vinod E. Nambudiri, MD, MBA, MPH, is affiliated with Brigham and Women's Hospital and specializes in Dermatology and Internal Medicine.

At the 2026 AAD Annual Meeting, Nambudiri spoke on various points, including how emerging AI tools may help reduce administrative burden in dermatology.

What Changes Is AI Making in Dermatology? With Vinod Nambudiri, MD, MBA, MPH

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

New psoriasis data show durable, rapid skin clearance with modern biologics, spotlighting bimekizumab’s four-year remission and patient-tailored selection.

Video Series

Treatment Selection in Psoriasis

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Teplizumab is now approved to treat stage 2 type 1 diabetes in kids 1 year and older.

FDA News

FDA Expands Teplizumab Approval to Children 1 Year & Older to Delay Type 1 Diabetes Onset

Explore how psoriasis biologics differ—TNF vs IL‑23/IL‑17—why classes matter, and what targeted therapy means for safety and results.

Latest News

Triple-Combination Blood Pressure Pill Reduces Ischemic Stroke Risk, With Craig Anderson, PhD

Lonapegsomatropin Proves Long-Term Benefit for Adult GHD in Phase 3 foresiGHt Extension Trial

FDA Expands Dupilumab to Children Aged 2 to 11 Years With Uncontrolled CSU

ICS Not Linked to Birth Defect Risk in Early Pregnancy, With Anick Bérard, PhD

Teplizumab Expansion Redefines Early Type 1 Diabetes Intervention, With Rachael Sood, NP